董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William K. McVicar | 男 | Chair of the Board and Director | 68 | 5.00万美元 | 0.0018 | 2026-07-14 |
| Jonathan Lieber | 男 | Director | 56 | 3.35万美元 | 0.0018 | 2026-07-14 |
| Paul Lammers | 男 | Director | 68 | 3.00万美元 | 0.0017 | 2026-07-14 |
| Tess Burleson | 女 | Director | 59 | 3.35万美元 | 0.0018 | 2026-07-14 |
| Frederick E. Pierce | 男 | Chief Executive Officer and Director | 64 | 22.50万美元 | 0.51 | 2026-07-14 |
| Patricia Gauthier | 女 | Director | 49 | 未披露 | 未持股 | 2026-07-14 |
| Arnold C. Hanish | 男 | Director | 78 | 4.00万美元 | 0.0018 | 2026-07-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark J. Rosenblum | 男 | Chief Financial Officer and Executive Vice President of Finance | 72 | 56.90万美元 | 0.17 | 2026-07-14 |
| Frederick E. Pierce | 男 | Chief Executive Officer and Director | 64 | 22.50万美元 | 0.51 | 2026-07-14 |
| Barbara Hibner | 女 | Chief Scientific Officer | 65 | 22.50万美元 | 0.10 | 2026-07-14 |
| Peter Marschel | 男 | Chief Business Officer | 52 | 22.51万美元 | 0.10 | 2026-07-14 |
董事简历
中英对照 | 中文 | 英文- William K. McVicar
-
William K. McVicar，自2019年7月完成反向收购以来，一直担任Salarius董事会成员。在收购完成之前，McVicar博士自2017年8月起担任Flex Pharma， Inc.（“Flex Pharma”）的董事会成员，并于2017年7月至2019年7月担任其首席执行官。McVicar博士于2017年4月加入Flex Pharma，担任研发总裁。在加入Flex Pharma之前，他还担任Neuromity Therapeutics， LLC的总裁兼首席执行官（2021年11月以来），并担任Satellos Biosciences， Inc.的首席运营官（代理）（2020年7月以来）。此外，2007年9月至2017年4月，他在Inotek Pharmaceuticals Corporation任职期间担任药物开发执行副总裁、首席科学官和总裁。McVicar博士还在serpracor， Inc .， Novartis AG和RPR Gencell （Rhone Poulenc Rorer的基因和细胞治疗部门）担任多个职位。他持有纽约州立大学College at Oneonta的化学学士学位和Vermont大学的化学博士学位。
William K. McVicar has served as a member of the Board of Directors since the completion of the reverse acquisition in July 2019. Prior to completion of the acquisition, Dr. McVicar served as a member of the board of directors of Flex Pharma, Inc. ("Flex Pharma") since August 2017, and served as its chief executive officer from July 2017 to July 2019. Dr. McVicar joined Flex Pharma in April 2017 as President of Research & Development. Prior to joining Flex Pharma, Dr. McVicar also serves as president and CEO of Neuromity Therapeutics, LLC since November 2021 and serves as Chief Operating Officer (acting) at Satellos Biosciences, Inc. since July 2020. Additionally, Dr. McVicar served as Executive Vice President of pharmaceutical development, chief scientific officer and president during his tenure at Inotek Pharmaceuticals Corporation from September 2007 to April 2017. Dr. McVicar also held various positions at Sepracor, Inc., Novartis AG and RPR Gencell, the Gene and Cell Therapy Division of Rhone Poulenc Rorer. Dr. McVicar earned his B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont. - William K. McVicar，自2019年7月完成反向收购以来，一直担任Salarius董事会成员。在收购完成之前，McVicar博士自2017年8月起担任Flex Pharma， Inc.（“Flex Pharma”）的董事会成员，并于2017年7月至2019年7月担任其首席执行官。McVicar博士于2017年4月加入Flex Pharma，担任研发总裁。在加入Flex Pharma之前，他还担任Neuromity Therapeutics， LLC的总裁兼首席执行官（2021年11月以来），并担任Satellos Biosciences， Inc.的首席运营官（代理）（2020年7月以来）。此外，2007年9月至2017年4月，他在Inotek Pharmaceuticals Corporation任职期间担任药物开发执行副总裁、首席科学官和总裁。McVicar博士还在serpracor， Inc .， Novartis AG和RPR Gencell （Rhone Poulenc Rorer的基因和细胞治疗部门）担任多个职位。他持有纽约州立大学College at Oneonta的化学学士学位和Vermont大学的化学博士学位。
- William K. McVicar has served as a member of the Board of Directors since the completion of the reverse acquisition in July 2019. Prior to completion of the acquisition, Dr. McVicar served as a member of the board of directors of Flex Pharma, Inc. ("Flex Pharma") since August 2017, and served as its chief executive officer from July 2017 to July 2019. Dr. McVicar joined Flex Pharma in April 2017 as President of Research & Development. Prior to joining Flex Pharma, Dr. McVicar also serves as president and CEO of Neuromity Therapeutics, LLC since November 2021 and serves as Chief Operating Officer (acting) at Satellos Biosciences, Inc. since July 2020. Additionally, Dr. McVicar served as Executive Vice President of pharmaceutical development, chief scientific officer and president during his tenure at Inotek Pharmaceuticals Corporation from September 2007 to April 2017. Dr. McVicar also held various positions at Sepracor, Inc., Novartis AG and RPR Gencell, the Gene and Cell Therapy Division of Rhone Poulenc Rorer. Dr. McVicar earned his B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont.
- Jonathan Lieber
-
Jonathan Lieber，自2020年6月起担任Salarius董事会成员。自2023年2月以来，他一直担任Rallybio Corporation（纳斯达克股票代码：RLYB）的首席财务官和财务主管，这是一家临床阶段的生物技术公司，致力于识别和加速为患有严重和罕见疾病的患者开发改变生命的疗法。从2021年9月到2022年11月出售，他担任Applied Genetic Technologies Corporation（纳斯达克股票代码：AGTC）的首席财务官，这是一家临床阶段生物技术公司，专注于开发和商业化基于腺相关病毒（AAV）的基因疗法，用于治疗罕见和衰弱性疾病。从2018年12月到2021年9月，他担任Danforth Advisors LLC的董事总经理，该公司为医疗保健公司提供战略首席财务官咨询和外包会计服务。在此期间，他曾担任几家私营和公共医疗保健公司的临时首席财务官。从2015年7月到2019年9月，Lieber先生担任Histogenics Corporation（纳斯达克股票代码：HSGX）的首席财务官，这是一家为骨科市场开发产品的细胞治疗公司。他持有纽约大学Stern School of Business的金融工商管理硕士学位和Boston大学的工商管理学士学位。
Jonathan Lieber has served as a member of the Board of Directors since June 2020. Since February 2023, he has served as Chief Financial Officer and Treasurer of Rallybio Corporation (Nasdaq: RLYB), a clinical stage biotechnology company committed to identifying and accelerating the development of life transforming therapies for patients with severe and rare diseases. From September 2021 until its sale in November 2022, he served as Chief Financial Officer of Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno associated virus (AAV) based gene therapies for the treatment of rare and debilitating diseases. From December 2018 through September 2021, Mr. Lieber served as a Managing Director of Danforth Advisors LLC, a firm that provides strategic CFO advisory and outsourced accounting services to healthcare companies. In that capacity, he served as interim CFO for several private and public healthcare companies. From July 2015 through September 2019, Mr. Lieber was Chief Financial Officer of Histogenics Corporation (Nasdaq: HSGX) a cell therapy company developing products for the orthopedics market. Mr. Lieber received an M.B.A. in finance from the Stern School of Business of New York University and a B.S. in business administration from Boston University. - Jonathan Lieber，自2020年6月起担任Salarius董事会成员。自2023年2月以来，他一直担任Rallybio Corporation（纳斯达克股票代码：RLYB）的首席财务官和财务主管，这是一家临床阶段的生物技术公司，致力于识别和加速为患有严重和罕见疾病的患者开发改变生命的疗法。从2021年9月到2022年11月出售，他担任Applied Genetic Technologies Corporation（纳斯达克股票代码：AGTC）的首席财务官，这是一家临床阶段生物技术公司，专注于开发和商业化基于腺相关病毒（AAV）的基因疗法，用于治疗罕见和衰弱性疾病。从2018年12月到2021年9月，他担任Danforth Advisors LLC的董事总经理，该公司为医疗保健公司提供战略首席财务官咨询和外包会计服务。在此期间，他曾担任几家私营和公共医疗保健公司的临时首席财务官。从2015年7月到2019年9月，Lieber先生担任Histogenics Corporation（纳斯达克股票代码：HSGX）的首席财务官，这是一家为骨科市场开发产品的细胞治疗公司。他持有纽约大学Stern School of Business的金融工商管理硕士学位和Boston大学的工商管理学士学位。
- Jonathan Lieber has served as a member of the Board of Directors since June 2020. Since February 2023, he has served as Chief Financial Officer and Treasurer of Rallybio Corporation (Nasdaq: RLYB), a clinical stage biotechnology company committed to identifying and accelerating the development of life transforming therapies for patients with severe and rare diseases. From September 2021 until its sale in November 2022, he served as Chief Financial Officer of Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno associated virus (AAV) based gene therapies for the treatment of rare and debilitating diseases. From December 2018 through September 2021, Mr. Lieber served as a Managing Director of Danforth Advisors LLC, a firm that provides strategic CFO advisory and outsourced accounting services to healthcare companies. In that capacity, he served as interim CFO for several private and public healthcare companies. From July 2015 through September 2019, Mr. Lieber was Chief Financial Officer of Histogenics Corporation (Nasdaq: HSGX) a cell therapy company developing products for the orthopedics market. Mr. Lieber received an M.B.A. in finance from the Stern School of Business of New York University and a B.S. in business administration from Boston University.
- Paul Lammers
-
Paul LammersM.D.自2019年7月起担任Salarius董事会成员和首席独立董事。自2018年1月以来，Lammers博士一直担任免疫疗法公司Triumvira Immunologics的总裁兼首席执行官。加入Triumvira Immunologics之前，Lammers曾担任Mirna Theraputics（现为Synlogic Inc.）总裁、首席执行官和董事。从2009年11月至2017年8月担任肿瘤公司Sybx的总裁，从2009年2月至2009年10月担任生物制药公司Repros Theraputics的总裁，从2002年至2008年担任生物制药公司Merk KGaA的子公司EMD Serono Inc.的首席医疗官。此外，从1992年到2002年，Lammers博士在Biocyte Theraputics，Inc.（一家生物制药公司），Zonagen，Inc.（一家生物制药公司），Hoechst Marion Roussel，Inc.（现为Aventis Pharmaceuticals Inc.）（一家制药公司），Organon Inc.（一家制药公司），Organon International（一家制药公司）担任各种执行或管理职务。Lammers博士在荷兰拉达布大学（Radaboud University）获得生物学和生殖内分泌学硕士学位，在拉达布大学（Radaboud University）获得医学博士学位。
Paul Lammers has served as a member of the Board of Directors since July 2019 and previously served as the Company's lead independent director. In February 2024, Dr. Lammers retired as CEO of Triumvira Immunologics, a privately held engineered T cell therapy company and for which he raised over $125 million from leading venture firms, where he served starting in 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing (Nasdaq: MRNA) in 2015. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono. During his early industry tenure, Dr. Lammers also held various executive and senior management positions in clinical development, medical and regulatory affairs at different pharmaceutical companies, as well as at small public and privately held biotechnology companies. Dr. Lammers serves as Director for private oncology biotechnology company Immunomet Therapeutics, and private oncology biotechnology company Diakonos Oncology. Dr. Lammers obtained both his Master of Science in Biology and his Medical Degree from Radboud University, Nijmegen, The Netherlands. - Paul LammersM.D.自2019年7月起担任Salarius董事会成员和首席独立董事。自2018年1月以来，Lammers博士一直担任免疫疗法公司Triumvira Immunologics的总裁兼首席执行官。加入Triumvira Immunologics之前，Lammers曾担任Mirna Theraputics（现为Synlogic Inc.）总裁、首席执行官和董事。从2009年11月至2017年8月担任肿瘤公司Sybx的总裁，从2009年2月至2009年10月担任生物制药公司Repros Theraputics的总裁，从2002年至2008年担任生物制药公司Merk KGaA的子公司EMD Serono Inc.的首席医疗官。此外，从1992年到2002年，Lammers博士在Biocyte Theraputics，Inc.（一家生物制药公司），Zonagen，Inc.（一家生物制药公司），Hoechst Marion Roussel，Inc.（现为Aventis Pharmaceuticals Inc.）（一家制药公司），Organon Inc.（一家制药公司），Organon International（一家制药公司）担任各种执行或管理职务。Lammers博士在荷兰拉达布大学（Radaboud University）获得生物学和生殖内分泌学硕士学位，在拉达布大学（Radaboud University）获得医学博士学位。
- Paul Lammers has served as a member of the Board of Directors since July 2019 and previously served as the Company's lead independent director. In February 2024, Dr. Lammers retired as CEO of Triumvira Immunologics, a privately held engineered T cell therapy company and for which he raised over $125 million from leading venture firms, where he served starting in 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing (Nasdaq: MRNA) in 2015. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono. During his early industry tenure, Dr. Lammers also held various executive and senior management positions in clinical development, medical and regulatory affairs at different pharmaceutical companies, as well as at small public and privately held biotechnology companies. Dr. Lammers serves as Director for private oncology biotechnology company Immunomet Therapeutics, and private oncology biotechnology company Diakonos Oncology. Dr. Lammers obtained both his Master of Science in Biology and his Medical Degree from Radboud University, Nijmegen, The Netherlands.
- Tess Burleson
-
Tess Burleson自2019年7月起担任Salarius’；董事会成员。Burleson自2007年起担任Translational Genomics Research Institute（一家非营利研究机构）首席运营官，自2009年起担任TGEN Health Ventures，LLC（一家风险投资公司）总裁。在加入Translational Genomics Research Institute之前，Burleson女士从1997年到2007年担任Lovelace Medical Foundation的首席财务官，从1993年到1997年担任Lovelace Scientific Resources的总裁，从1990年到1993年担任毕马威会计师事务所（KPMG）的税务、审计与咨询服务高级助理。Burleson女士在新墨西哥大学（University of New Mexico）安德森管理研究生院（Anderson Graduate School of Management）获得会计学学士学位，并在新墨西哥大学（University of New Mexico）获得工商管理硕士学位。
Tess Burleson has served as a member of the Board of Directors since July 2019. Ms. Burleson is a Certified Public Accountant and has served as the chief operating officer of TGen, a Medical R&D organization, since 2007, and has served as the president of TGen Health Ventures, LLC, a venture capital company, since 2009. She also serves as an advisor to bankers and investors in the life sciences industry. Prior to joining TGen, Ms. Burleson served as the chief financial officer at Lovelace Health System enterprises from 1997 to 2007, president at Lovelace Scientific Resources from 1993 to 1997, and as a senior associate at KPMG from 1990 to 1993. Ms. Burleson earned an advanced finance certification from The Wharton School at the University of Pennsylvania, a B.B.A. from Robert O. Anderson School of Business at the University of New Mexico and her M.B.A. from the Anderson Graduate School of Management at the University of New Mexico. - Tess Burleson自2019年7月起担任Salarius’；董事会成员。Burleson自2007年起担任Translational Genomics Research Institute（一家非营利研究机构）首席运营官，自2009年起担任TGEN Health Ventures，LLC（一家风险投资公司）总裁。在加入Translational Genomics Research Institute之前，Burleson女士从1997年到2007年担任Lovelace Medical Foundation的首席财务官，从1993年到1997年担任Lovelace Scientific Resources的总裁，从1990年到1993年担任毕马威会计师事务所（KPMG）的税务、审计与咨询服务高级助理。Burleson女士在新墨西哥大学（University of New Mexico）安德森管理研究生院（Anderson Graduate School of Management）获得会计学学士学位，并在新墨西哥大学（University of New Mexico）获得工商管理硕士学位。
- Tess Burleson has served as a member of the Board of Directors since July 2019. Ms. Burleson is a Certified Public Accountant and has served as the chief operating officer of TGen, a Medical R&D organization, since 2007, and has served as the president of TGen Health Ventures, LLC, a venture capital company, since 2009. She also serves as an advisor to bankers and investors in the life sciences industry. Prior to joining TGen, Ms. Burleson served as the chief financial officer at Lovelace Health System enterprises from 1997 to 2007, president at Lovelace Scientific Resources from 1993 to 1997, and as a senior associate at KPMG from 1990 to 1993. Ms. Burleson earned an advanced finance certification from The Wharton School at the University of Pennsylvania, a B.B.A. from Robert O. Anderson School of Business at the University of New Mexico and her M.B.A. from the Anderson Graduate School of Management at the University of New Mexico.
- Frederick E. Pierce
-
弗雷德里克·皮尔斯（Frederick E. Pierce）自2020年与他人共同创立Decoy以来，一直担任该公司的首席执行官兼董事。从2022年9月到2024年11月，Pierce先生担任药物发现公司Innovation1 Biotech，Inc.的执行官。Pierce先生还是波士顿/剑桥加拿大领事馆医疗保健和技术加速器的顾问，也是新英格兰加拿大企业家协会的董事会成员，他是该协会生命科学领导委员会的主席。从2017年到2020年，Pierce先生担任生命科学咨询公司Bionest Partners的高级顾问。
Frederick E. Pierce has served as a member of the Board of Directors and as the Company's Chief Executive Officer since November 12, 2025. Mr. Pierce was a co founder of Legacy Decoy and served as Legacy Decoy's Chief Executive Officer and a member of its board of directors from 2020 until the closing of the Merger. From September 2022 until November 2024, Mr. Pierce served as an executive officer of Innovation1 Biotech, Inc., a drug discovery company. Mr. Pierce is also an advisor to the Canadian Consulate of Boston/Cambridge's Healthcare and Technology Accelerator and a board member of the Canadian Entrepreneurs of New England, where he is Chairman of the Life Sciences Leadership Council. From 2017 through 2020, Mr. Pierce served as a Senior Advisor for Bionest Partners, a life sciences consulting company. Mr. Pierce is a biotech entrepreneur with over 20 years of increasing senior leadership and operating experience building successful biotechnology companies. - 弗雷德里克·皮尔斯（Frederick E. Pierce）自2020年与他人共同创立Decoy以来，一直担任该公司的首席执行官兼董事。从2022年9月到2024年11月，Pierce先生担任药物发现公司Innovation1 Biotech，Inc.的执行官。Pierce先生还是波士顿/剑桥加拿大领事馆医疗保健和技术加速器的顾问，也是新英格兰加拿大企业家协会的董事会成员，他是该协会生命科学领导委员会的主席。从2017年到2020年，Pierce先生担任生命科学咨询公司Bionest Partners的高级顾问。
- Frederick E. Pierce has served as a member of the Board of Directors and as the Company's Chief Executive Officer since November 12, 2025. Mr. Pierce was a co founder of Legacy Decoy and served as Legacy Decoy's Chief Executive Officer and a member of its board of directors from 2020 until the closing of the Merger. From September 2022 until November 2024, Mr. Pierce served as an executive officer of Innovation1 Biotech, Inc., a drug discovery company. Mr. Pierce is also an advisor to the Canadian Consulate of Boston/Cambridge's Healthcare and Technology Accelerator and a board member of the Canadian Entrepreneurs of New England, where he is Chairman of the Life Sciences Leadership Council. From 2017 through 2020, Mr. Pierce served as a Senior Advisor for Bionest Partners, a life sciences consulting company. Mr. Pierce is a biotech entrepreneur with over 20 years of increasing senior leadership and operating experience building successful biotechnology companies.
- Patricia Gauthier
-
Patricia Gauthier自2025年以来一直担任Moderna高级副总裁兼澳大利亚、加拿大和英国区域主管，负责领导生物制造领域的端到端战略和运营、国家健康安全合作伙伴关系、研发合作以及市场和管道产品的商业化。她负责监督重要的区域投资、区域损益，以及直接和矩阵化团队的大约500名员工。此前，Gauthier女士曾在Moderna担任多个高级职务，包括Moderna加拿大公司的总经理，她从一开始就在那里建立了加拿大子公司，支持交付超过5000万剂新冠肺炎疫苗，并帮助确保与加拿大政府建立具有里程碑意义的生物制造合作伙伴关系。她还牵头创立了Moderna的全球罕见病业务，并定义了其全球战略、运营模式和走向市场的方式。在加入Moderna之前，Gauthier女士曾在GSK担任多个高级领导职务，涉及疫苗、专科护理、普通药物、市场准入和政府事务。在她职业生涯的早期，她在麦卡锡T é trault律师事务所从事法律工作。Gauthier女士在AdMare BioInnovations（加拿大私营公司）的董事会任职。她拥有HEC Montr é al的MBA学位和加拿大舍布鲁克大学的法学学士学位，拥有哈佛商学院（谈判）和IMD（领导力）的高管教育。
Patricia Gauthier has served as Senior Vice President, Regional Head for Australia, Canada and the United Kingdom at Moderna since 2025, where she leads end to end strategy and operations across biomanufacturing, national health security partnerships, R&D collaborations and commercialization of in market and pipeline products. She oversees significant regional investment, regional P&L, and approximately 500 employees across direct and matrixed teams. Previously, Ms. Gauthier held several senior roles at Moderna, including General Manager of Moderna Canada, where she built the Canadian affiliate from inception, supported delivery of more than 50 million COVID 19 vaccine doses, and helped secure a landmark biomanufacturing partnership with the Government of Canada. She also led the creation of Moderna's global rare disease business and defining its global strategy, operating model and go to market approach. Before Moderna, Ms. Gauthier held multiple senior leadership roles at GSK across vaccines, specialty care, general medicines, market access and government affairs. Earlier in her career, she practiced law at McCarthy Tétrault LLP. Ms. Gauthier serves on the boards of AdMare BioInnovations (Canadian private company). She holds an MBA from HEC Montréal and an LL.B. from the Université de Sherbrooke in Canada, with executive education from Harvard Business School (negotiation) and IMD (leadership). - Patricia Gauthier自2025年以来一直担任Moderna高级副总裁兼澳大利亚、加拿大和英国区域主管，负责领导生物制造领域的端到端战略和运营、国家健康安全合作伙伴关系、研发合作以及市场和管道产品的商业化。她负责监督重要的区域投资、区域损益，以及直接和矩阵化团队的大约500名员工。此前，Gauthier女士曾在Moderna担任多个高级职务，包括Moderna加拿大公司的总经理，她从一开始就在那里建立了加拿大子公司，支持交付超过5000万剂新冠肺炎疫苗，并帮助确保与加拿大政府建立具有里程碑意义的生物制造合作伙伴关系。她还牵头创立了Moderna的全球罕见病业务，并定义了其全球战略、运营模式和走向市场的方式。在加入Moderna之前，Gauthier女士曾在GSK担任多个高级领导职务，涉及疫苗、专科护理、普通药物、市场准入和政府事务。在她职业生涯的早期，她在麦卡锡T é trault律师事务所从事法律工作。Gauthier女士在AdMare BioInnovations（加拿大私营公司）的董事会任职。她拥有HEC Montr é al的MBA学位和加拿大舍布鲁克大学的法学学士学位，拥有哈佛商学院（谈判）和IMD（领导力）的高管教育。
- Patricia Gauthier has served as Senior Vice President, Regional Head for Australia, Canada and the United Kingdom at Moderna since 2025, where she leads end to end strategy and operations across biomanufacturing, national health security partnerships, R&D collaborations and commercialization of in market and pipeline products. She oversees significant regional investment, regional P&L, and approximately 500 employees across direct and matrixed teams. Previously, Ms. Gauthier held several senior roles at Moderna, including General Manager of Moderna Canada, where she built the Canadian affiliate from inception, supported delivery of more than 50 million COVID 19 vaccine doses, and helped secure a landmark biomanufacturing partnership with the Government of Canada. She also led the creation of Moderna's global rare disease business and defining its global strategy, operating model and go to market approach. Before Moderna, Ms. Gauthier held multiple senior leadership roles at GSK across vaccines, specialty care, general medicines, market access and government affairs. Earlier in her career, she practiced law at McCarthy Tétrault LLP. Ms. Gauthier serves on the boards of AdMare BioInnovations (Canadian private company). She holds an MBA from HEC Montréal and an LL.B. from the Université de Sherbrooke in Canada, with executive education from Harvard Business School (negotiation) and IMD (leadership).
- Arnold C. Hanish
-
Arnold C. Hanish，自2019年7月起担任Salarius董事会成员。他曾担任Eli Lilly and Company（一家制药公司）的各种管理职务，包括副总裁兼首席会计官。在Eli Lilly and Company之前，Hanish先生从1970年到1984年在Arthur Young & Company（现为Ernst & Young）担任多个职位，包括从1979年到1984年担任印第安纳波利斯办事处的税务主管。他曾担任Deloitte and Touche， LLP（一家专业服务公司）、Audit Quality Review Council（2013年至2023年）的成员。此外，自2012年9月起，他担任生物制药公司Omeros Corporation （Nasdaq：OMER）的董事会成员，并担任其审计委员会主席。从2007年到2010年，Hanish先生担任公司报告财务执行国际委员会主席，并在其SEC和上市公司会计监督委员会（PCAOB）小组委员会任职。2016年，他入选金融高管国际名人堂（Financial Executives International Hall of Fame）。从2004年到2008年以及2011年和2012年，Hanish先生是PCAOB（一个非营利性审计监督组织）常设咨询小组的成员。自2010年以来，Hanish先生一直担任商业咨询委员会的院长，最近获得了辛辛那提大学商学院的杰出服务奖。他在Cincinnati大学获得会计学工商管理硕士学位，是印第安纳州和俄亥俄州的注册会计师。
Arnold C. Hanish has served as a member of the Board of Directors since July 2019. Mr. Hanish served in various management roles at Eli Lilly and Company, a pharmaceutical company, including Vice President and Chief Accounting Officer. Prior to Eli Lilly and Company, Mr. Hanish held numerous positions at Arthur Young & Company (currently Ernst & Young) from 1970 to 1984, including being the Director of Tax in the Indianapolis office from 1979 to 1984. Mr. Hanish served as a member of the Deloitte and Touche, LLP, a professional services company, Audit Quality Review Council from 2013 to 2023. In addition, since September 2012, Mr. Hanish has served on the board of directors of Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company, and chairs its Audit Committee. From 2007 to 2010, Mr. Hanish served as the Chairperson of the Financial Executives International Committee on Corporate Reporting and was on their SEC and Public Company Accounting Oversight Board ("PCAOB") subcommittees. In 2016, Mr. Hanish was inducted into the Financial Executives International Hall of Fame. From 2004 to 2008 and again in 2011 and 2012, Mr. Hanish was a member of the Standing Advisory Group of the PCAOB, a nonprofit audit oversight organization. Since 2010, Mr. Hanish has served on the Dean of the College of Business's Business Advisory Council and recently received the Distinguished Service Award from the college of business at the University of Cincinnati. Mr. Hanish earned a B.B.A. in Accounting from the University of Cincinnati and is a licensed CPA in Indiana and Ohio. - Arnold C. Hanish，自2019年7月起担任Salarius董事会成员。他曾担任Eli Lilly and Company（一家制药公司）的各种管理职务，包括副总裁兼首席会计官。在Eli Lilly and Company之前，Hanish先生从1970年到1984年在Arthur Young & Company（现为Ernst & Young）担任多个职位，包括从1979年到1984年担任印第安纳波利斯办事处的税务主管。他曾担任Deloitte and Touche， LLP（一家专业服务公司）、Audit Quality Review Council（2013年至2023年）的成员。此外，自2012年9月起，他担任生物制药公司Omeros Corporation （Nasdaq：OMER）的董事会成员，并担任其审计委员会主席。从2007年到2010年，Hanish先生担任公司报告财务执行国际委员会主席，并在其SEC和上市公司会计监督委员会（PCAOB）小组委员会任职。2016年，他入选金融高管国际名人堂（Financial Executives International Hall of Fame）。从2004年到2008年以及2011年和2012年，Hanish先生是PCAOB（一个非营利性审计监督组织）常设咨询小组的成员。自2010年以来，Hanish先生一直担任商业咨询委员会的院长，最近获得了辛辛那提大学商学院的杰出服务奖。他在Cincinnati大学获得会计学工商管理硕士学位，是印第安纳州和俄亥俄州的注册会计师。
- Arnold C. Hanish has served as a member of the Board of Directors since July 2019. Mr. Hanish served in various management roles at Eli Lilly and Company, a pharmaceutical company, including Vice President and Chief Accounting Officer. Prior to Eli Lilly and Company, Mr. Hanish held numerous positions at Arthur Young & Company (currently Ernst & Young) from 1970 to 1984, including being the Director of Tax in the Indianapolis office from 1979 to 1984. Mr. Hanish served as a member of the Deloitte and Touche, LLP, a professional services company, Audit Quality Review Council from 2013 to 2023. In addition, since September 2012, Mr. Hanish has served on the board of directors of Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company, and chairs its Audit Committee. From 2007 to 2010, Mr. Hanish served as the Chairperson of the Financial Executives International Committee on Corporate Reporting and was on their SEC and Public Company Accounting Oversight Board ("PCAOB") subcommittees. In 2016, Mr. Hanish was inducted into the Financial Executives International Hall of Fame. From 2004 to 2008 and again in 2011 and 2012, Mr. Hanish was a member of the Standing Advisory Group of the PCAOB, a nonprofit audit oversight organization. Since 2010, Mr. Hanish has served on the Dean of the College of Business's Business Advisory Council and recently received the Distinguished Service Award from the college of business at the University of Cincinnati. Mr. Hanish earned a B.B.A. in Accounting from the University of Cincinnati and is a licensed CPA in Indiana and Ohio.
高管简历
中英对照 | 中文 | 英文- Mark J. Rosenblum
Mark J. Rosenblum，自2019年9月起担任Salarius Pharmaceuticals, Inc.财务执行副总裁兼首席财务官。在2019年9月之前，Rosenblum先生自2019年2月起担任Salarius Pharmaceuticals， Inc.的财务顾问。在加入Salarius Pharmaceuticals， Inc.之前，Rosenblum先生于2017年12月至2019年3月担任ActiveCare， Inc.（纳斯达克股票代码：ACAR）的董事长、首席执行官兼董事，这是一家医疗保健公司，ActiveCare， Inc.被出售给Biotelemetry， Inc.（现为Royal Philips（纽约证券交易所代码：PHG））。Rosenblum先生从2014年到2017年担任多家公司的财务顾问。此前，2010年1月至2014年4月，Rosenblum先生担任生物技术公司Advaxis， Inc.（纳斯达克股票代码：ADXS）的首席财务官。从1985年到2003年，Rosenblum先生受雇于Wellman， Inc.（全球公共化学品制造商，随后被DAK Americas收购），担任各种职务，包括首席会计官。Rosenblum先生持有南卡罗来纳大学的会计硕士学位和会计学士学位。Rosenblum先生于1977年在Haskins & Sells开始他的职业生涯，Haskins & Sells是一名注册会计师（目前被称为德勤），是一名执业会计师超过30年，目前是美国注册会计师协会的成员。
Mark J. Rosenblum has served as the Company's Executive Vice President of Finance and Chief Financial Officer since September 2019. In addition, Mr. Rosenblum served as the Company's principal executive officer as Acting Chief Executive Officer from August 17, 2025 until November 12, 2025, the effective date on which Mr. Pierce was appointed as the Company's Chief Executive Officer. Prior to September 2019, Mr. Rosenblum served as a financial consultant to the Company since February 2019. Prior to joining the Company, Mr. Rosenblum served as chairman, chief executive officer and a director of ActiveCare, Inc. (Nasdaq: ACAR), a healthcare company, from December 2017 to March 2019, which was sold to Biotelemetry, Inc. (now Royal Philips (NYSE: PHG)). Mr. Rosenblum worked as a financial consultant for various companies from 2014 to 2017. Prior to that, Mr. Rosenblum served as the chief financial officer of Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company, from January 2010 to April 2014. From 1985 through 2003, Mr. Rosenblum was employed by Wellman, Inc., a global public chemical manufacturer, which was subsequently acquired by DAK Americas, serving in various capacities including chief accounting officer. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina. Mr. Rosenblum began his career in 1977 with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years, and is currently a member of the American Institute of Certified Public Accountants.- Mark J. Rosenblum，自2019年9月起担任Salarius Pharmaceuticals, Inc.财务执行副总裁兼首席财务官。在2019年9月之前，Rosenblum先生自2019年2月起担任Salarius Pharmaceuticals， Inc.的财务顾问。在加入Salarius Pharmaceuticals， Inc.之前，Rosenblum先生于2017年12月至2019年3月担任ActiveCare， Inc.（纳斯达克股票代码：ACAR）的董事长、首席执行官兼董事，这是一家医疗保健公司，ActiveCare， Inc.被出售给Biotelemetry， Inc.（现为Royal Philips（纽约证券交易所代码：PHG））。Rosenblum先生从2014年到2017年担任多家公司的财务顾问。此前，2010年1月至2014年4月，Rosenblum先生担任生物技术公司Advaxis， Inc.（纳斯达克股票代码：ADXS）的首席财务官。从1985年到2003年，Rosenblum先生受雇于Wellman， Inc.（全球公共化学品制造商，随后被DAK Americas收购），担任各种职务，包括首席会计官。Rosenblum先生持有南卡罗来纳大学的会计硕士学位和会计学士学位。Rosenblum先生于1977年在Haskins & Sells开始他的职业生涯，Haskins & Sells是一名注册会计师（目前被称为德勤），是一名执业会计师超过30年，目前是美国注册会计师协会的成员。
- Mark J. Rosenblum has served as the Company's Executive Vice President of Finance and Chief Financial Officer since September 2019. In addition, Mr. Rosenblum served as the Company's principal executive officer as Acting Chief Executive Officer from August 17, 2025 until November 12, 2025, the effective date on which Mr. Pierce was appointed as the Company's Chief Executive Officer. Prior to September 2019, Mr. Rosenblum served as a financial consultant to the Company since February 2019. Prior to joining the Company, Mr. Rosenblum served as chairman, chief executive officer and a director of ActiveCare, Inc. (Nasdaq: ACAR), a healthcare company, from December 2017 to March 2019, which was sold to Biotelemetry, Inc. (now Royal Philips (NYSE: PHG)). Mr. Rosenblum worked as a financial consultant for various companies from 2014 to 2017. Prior to that, Mr. Rosenblum served as the chief financial officer of Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company, from January 2010 to April 2014. From 1985 through 2003, Mr. Rosenblum was employed by Wellman, Inc., a global public chemical manufacturer, which was subsequently acquired by DAK Americas, serving in various capacities including chief accounting officer. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina. Mr. Rosenblum began his career in 1977 with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years, and is currently a member of the American Institute of Certified Public Accountants.
- Frederick E. Pierce
弗雷德里克·皮尔斯（Frederick E. Pierce）自2020年与他人共同创立Decoy以来，一直担任该公司的首席执行官兼董事。从2022年9月到2024年11月，Pierce先生担任药物发现公司Innovation1 Biotech，Inc.的执行官。Pierce先生还是波士顿/剑桥加拿大领事馆医疗保健和技术加速器的顾问，也是新英格兰加拿大企业家协会的董事会成员，他是该协会生命科学领导委员会的主席。从2017年到2020年，Pierce先生担任生命科学咨询公司Bionest Partners的高级顾问。
Frederick E. Pierce has served as a member of the Board of Directors and as the Company's Chief Executive Officer since November 12, 2025. Mr. Pierce was a co founder of Legacy Decoy and served as Legacy Decoy's Chief Executive Officer and a member of its board of directors from 2020 until the closing of the Merger. From September 2022 until November 2024, Mr. Pierce served as an executive officer of Innovation1 Biotech, Inc., a drug discovery company. Mr. Pierce is also an advisor to the Canadian Consulate of Boston/Cambridge's Healthcare and Technology Accelerator and a board member of the Canadian Entrepreneurs of New England, where he is Chairman of the Life Sciences Leadership Council. From 2017 through 2020, Mr. Pierce served as a Senior Advisor for Bionest Partners, a life sciences consulting company. Mr. Pierce is a biotech entrepreneur with over 20 years of increasing senior leadership and operating experience building successful biotechnology companies.- 弗雷德里克·皮尔斯（Frederick E. Pierce）自2020年与他人共同创立Decoy以来，一直担任该公司的首席执行官兼董事。从2022年9月到2024年11月，Pierce先生担任药物发现公司Innovation1 Biotech，Inc.的执行官。Pierce先生还是波士顿/剑桥加拿大领事馆医疗保健和技术加速器的顾问，也是新英格兰加拿大企业家协会的董事会成员，他是该协会生命科学领导委员会的主席。从2017年到2020年，Pierce先生担任生命科学咨询公司Bionest Partners的高级顾问。
- Frederick E. Pierce has served as a member of the Board of Directors and as the Company's Chief Executive Officer since November 12, 2025. Mr. Pierce was a co founder of Legacy Decoy and served as Legacy Decoy's Chief Executive Officer and a member of its board of directors from 2020 until the closing of the Merger. From September 2022 until November 2024, Mr. Pierce served as an executive officer of Innovation1 Biotech, Inc., a drug discovery company. Mr. Pierce is also an advisor to the Canadian Consulate of Boston/Cambridge's Healthcare and Technology Accelerator and a board member of the Canadian Entrepreneurs of New England, where he is Chairman of the Life Sciences Leadership Council. From 2017 through 2020, Mr. Pierce served as a Senior Advisor for Bionest Partners, a life sciences consulting company. Mr. Pierce is a biotech entrepreneur with over 20 years of increasing senior leadership and operating experience building successful biotechnology companies.
- Barbara Hibner
芭芭拉·希布纳（Barbara Hibner）自2020年共同创立公司以来，一直担任Decoy的首席科学官、董事和董事会主席。2017年1月至2020年4月，Hibner博士是PercepTX的联合创始人兼首席执行官，PercepTX是一家靶向癌症免疫治疗公司，专注于通过计算建模和定量药理学来发现和开发新型抗体药物偶联物。在此之前，她曾在拜耳制药、Chiron、Millennium和武田制药担任一系列科学和管理职务，担任发现、药理学和研究质量职务。Hibner博士的工作为索拉非尼和ixazomib这两种小分子药物的批准做出了贡献。
Barbara Hibner has served as the Company's Chief Scientific Officer since November 12, 2025. Dr. Hibner was a co founder of Legacy Decoy and served as its Chief Scientific Officer, director and Board Chair from 2020 until the closing of the Merger. From January 2017 to April 2020, Dr. Hibner was co founder and Chief Executive Officer of PercepTx, a targeted cancer immunotherapy company focused on using computational modeling and quantitative pharmacology to discover and develop novel antibody drug conjugates. Prior to that, she served in a range of scientific and managerial positions in discovery, pharmacology and research quality roles at Bayer Pharmaceuticals, Chiron, Millennium and Takeda Pharmaceuticals. Dr. Hibner's work has contributed to the approval of two small molecule drugs, sorafenib and ixazomib.- 芭芭拉·希布纳（Barbara Hibner）自2020年共同创立公司以来，一直担任Decoy的首席科学官、董事和董事会主席。2017年1月至2020年4月，Hibner博士是PercepTX的联合创始人兼首席执行官，PercepTX是一家靶向癌症免疫治疗公司，专注于通过计算建模和定量药理学来发现和开发新型抗体药物偶联物。在此之前，她曾在拜耳制药、Chiron、Millennium和武田制药担任一系列科学和管理职务，担任发现、药理学和研究质量职务。Hibner博士的工作为索拉非尼和ixazomib这两种小分子药物的批准做出了贡献。
- Barbara Hibner has served as the Company's Chief Scientific Officer since November 12, 2025. Dr. Hibner was a co founder of Legacy Decoy and served as its Chief Scientific Officer, director and Board Chair from 2020 until the closing of the Merger. From January 2017 to April 2020, Dr. Hibner was co founder and Chief Executive Officer of PercepTx, a targeted cancer immunotherapy company focused on using computational modeling and quantitative pharmacology to discover and develop novel antibody drug conjugates. Prior to that, she served in a range of scientific and managerial positions in discovery, pharmacology and research quality roles at Bayer Pharmaceuticals, Chiron, Millennium and Takeda Pharmaceuticals. Dr. Hibner's work has contributed to the approval of two small molecule drugs, sorafenib and ixazomib.
- Peter Marschel
Peter Marschel，自2020年与他人共同创立Decoy以来，一直担任其首席业务官兼董事。直到2020年4月，Marschel先生还是PercepTX的联合创始人兼首席财务官，PercepTX是一家专注于Salarius制药 Pharmaceuticals，Inc.的靶向癌症免疫治疗加速器，通过计算建模和定量药理学快速提升基于临床前单抗的治疗资产的价值。在此之前，他曾在默沙东、福泰制药和武田制药担任一系列业务开发、分析和商业职务，包括在福泰制药为囊性纤维化特许经营提供领先的市场分析。
Peter Marschel has served as the Company's Chief Business Officer since November 12, 2025. Mr. Marschel was a co founder of Legacy Decoy and served as its Chief Business Officer and director from 2020 until the closing of the Merger. Until April 2020, Mr. Marschel was co founder and Chief Financial Officer of PercepTx, a targeted cancer immunotherapy accelerator focused on using computational modeling and quantitative pharmacology to rapidly increase the value of preclinical monoclonal antibody based therapeutic assets. Prior to that, he served in a range of business development, analytics, and commercial roles at Merck, Vertex Pharmaceuticals, and Takeda Pharmaceuticals, including leading market analytics for the cystic fibrosis franchise at Vertex Pharmaceuticals.- Peter Marschel，自2020年与他人共同创立Decoy以来，一直担任其首席业务官兼董事。直到2020年4月，Marschel先生还是PercepTX的联合创始人兼首席财务官，PercepTX是一家专注于Salarius制药 Pharmaceuticals，Inc.的靶向癌症免疫治疗加速器，通过计算建模和定量药理学快速提升基于临床前单抗的治疗资产的价值。在此之前，他曾在默沙东、福泰制药和武田制药担任一系列业务开发、分析和商业职务，包括在福泰制药为囊性纤维化特许经营提供领先的市场分析。
- Peter Marschel has served as the Company's Chief Business Officer since November 12, 2025. Mr. Marschel was a co founder of Legacy Decoy and served as its Chief Business Officer and director from 2020 until the closing of the Merger. Until April 2020, Mr. Marschel was co founder and Chief Financial Officer of PercepTx, a targeted cancer immunotherapy accelerator focused on using computational modeling and quantitative pharmacology to rapidly increase the value of preclinical monoclonal antibody based therapeutic assets. Prior to that, he served in a range of business development, analytics, and commercial roles at Merck, Vertex Pharmaceuticals, and Takeda Pharmaceuticals, including leading market analytics for the cystic fibrosis franchise at Vertex Pharmaceuticals.